Best Stocks: Daqo New Energy Corp. (NYSE:DQ), Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), Relypsa, Inc. (NASDAQ:RLYP), Vical Incorporated (NASDAQ:VICL), Syneron Medical Ltd. (NASDAQ:ELOS)

Daqo New Energy Corp. (NYSE:DQ) belongs to Technology sector. Its net profit margin is 8.30% and weekly performance is 7.03%. On last trading day company shares ended up $23.59. Daqo New Energy Corp. (NYSE:DQ) distance from 50-day simple moving average (SMA50) is -9.75%. Daqo New Energy Corp. (NYSE:DQ)‘s stock had its “buy” rating reissued by research analysts at Roth Capital in a report released on Wednesday. They currently have a $80.00 price target on the stock. Roth Capital’s target price suggests a potential upside of 209.36% from the stock’s previous close.

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) shares advanced 2.97% in last trading session and ended the day at $12.81. VNDA Gross Margin is 89.90% and its return on assets is 7.30%. Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) quarterly performance is 22.35%.On 26 May, Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) announced that it has received the 2015 Industry Innovation Award from the National Organization of Rare Disorders (NORD) in recognition of Vanda’s work in developing HETLIOZ® for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Relypsa, Inc. (NASDAQ:RLYP) belongs to Healthcare sector. Its weekly performance is -0.79%. On last trading day company shares ended up $36.50. Relypsa, Inc. (NASDAQ:RLYP) distance from 50-day simple moving average (SMA50) is 5.87%. On 2 June, Relypsa, Inc. (NASDAQ:RLYP) announced that on May 15, 2015, the compensation committee of the company’s board of directors granted five new employees options to purchase an aggregate of 22,400 shares of the company’s common stock with a per share exercise price of $35.49, the closing trading price on the grant date. The stock options were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5653(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.

On 05 June, Vical Incorporated (NASDAQ:VICL) shares remains unchanged and was closed at $0.98. VICL EPS growth in last 5 year was 20.80%. Vical Incorporated (NASDAQ:VICL) year to date (YTD) performance is -6.67%. On 21 May, Vical Incorporated (NASDAQ:VICL) announced the completion of enrollment in a Phase 2 trial of its therapeutic cytomegalovirus (CMV) vaccine in solid organ transplant recipients. ASP0113 is an investigational vaccine candidate under development for the prevention of CMV disease and associated complications in transplant recipients. Vical licensed the vaccine, ASP0113, to Astellas Pharma Inc. (TOKYO: 4503), which is conducting the Phase 2 trial and an ongoing pivotal Phase 3 trial in hematopoietic stem cell transplant recipients.

On 05 June, Syneron Medical Ltd. (NASDAQ:ELOS) shares remains unchanged and was closed at $10.92. ELOS EPS growth in last 5 year was 30.40%. Syneron Medical Ltd. (NASDAQ:ELOS) year to date (YTD) performance is 17.04%. On 4 June, Syneron Medical Ltd. (NASDAQ:ELOS) and Viora Ltd. and Viora Inc., a global manufacturer and distributor of medical aesthetic devices (“Viora”), announced today that they have entered into an agreement to settle Syneron’s patent infringement law suit against Viora in the United States and a business litigation in Israel.

Leave a Reply

Your email address will not be published. Required fields are marked *